CPHI China 2025: Meet Hebei Xingang Pharmaceutical at Booth W7A15

Event Details:

Date: June 24-26, 2025
Location: Shanghai New International Expo Center (Pudong)
Booth: W7A15

Hebei Xingang Pharmaceutical Co Ltd, a globally recognized leader in rifamycin series products and anti-tuberculosis (TB) APIs, will showcase its cutting-edge pharmaceutical solutions at the 23rd China International Pharmaceutical Ingredients Exhibition (CPHI China 2025). As a trusted partner to formulation manufacturers worldwide, the company invites industry professionals to explore its high-quality intermediates, advanced production capabilities, and commitment to global health innovation.

Why Visit Hebei Xingang Pharmaceutical at Booth W7A15?

1. Premium Rifamycin APIs & Intermediates

Specializing in rifampicin, rifapentine, rifaximin, and rifabutin, Hebei Xingang Pharmaceutical supplies critical ingredients for:

Tuberculosis (TB) treatment
Broad-spectrum antibiotic formulations
Gastrointestinal health products

Their product portfolio meets stringent pharmacopeia standards (BP/EP/USP) and serves clients in 50+ countries, including India, Germany, Brazil, and Africa.

2. State-of-the-Art Manufacturing & Compliance

WHO GMP Certified: Validated by global health authorities, ensuring compliance with international quality benchmarks.
Advanced Facilities:
- Computer-controlled fermentation and extraction workshops.
- Separate production lines for API synthesis, minimizing cross-contamination risks.
- Oil-free air compressors and closed vacuum systems for ultra-pure output.

3. Decades of Expertise & Innovation

Since 1996, the company has pioneered rifamycin biotechnology fermentation and built a reputation as a high-tech enterprise with:

Provincial-level R&D projects and patented fermentation optimizations.
In-house microbial labs with stainless steel fermentation tanks and modern testing instruments.

Global Reach, Local Expertise

Hebei Xingang Pharmaceutical’s products are trusted by leading pharmaceutical companies across:

Asia: India, Indonesia, Vietnam
Europe: Germany, Russia
Americas: Chile, Brazil
Africa: Key markets in TB-endemic regions

Their dedicated international sales team provides rapid response to regulatory audits, quality certifications, and supply chain inquiries.

Visit Booth W7A15 for:

Live demos of rifamycin S-Na salt and 3-F intermediates.
Discussions on custom synthesis and scalable API production.
Partnerships with a 20+ year industry veteran in anti-infective solutions.

Hebei Xingang Pharmaceutical: WHO-PQ & GMP Milestone

A Landmark Achievement in Global Health

Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO Approval

On June 9, 2025, the WHO announced that Hebei Xingang's Rifampicin API meets the highest standards for quality, safety, and manufacturing, marking its official entry into the WHO market to combat tuberculosis globally.

Explore the Milestone

Understanding the Core Pillars

This achievement rests on three critical foundations: the WHO's rigorous Prequalification program, universal Good Manufacturing Practices, and the vital role of Rifampicin.

🛡️

WHO Prequalification

A global benchmark for medicine quality, safety, and efficacy. The WHO-PQ program ensures that essential medicines meet stringent international standards, building trust in global supply chains.

🏭

GMP for APIs

The gold standard for pharmaceutical manufacturing. Good Manufacturing Practices ensure that Active Pharmaceutical Ingredients (APIs) are produced consistently and safely, minimizing all risks.

💊

Rifampicin's Role

A cornerstone antibiotic in the global fight against tuberculosis. Quality-assured Rifampicin is critical for effective treatment, preventing drug resistance, and saving lives.

The Path to Prequalification

Achieving WHO-PQ is an exhaustive process that validates every aspect of a product's lifecycle. Click each step to learn more about this rigorous journey.

1. Dossier Assessment

→

2. GMP Site Inspection

→

3. Quality Control Testing

→

4. Final Approval

Select a step above to see the details.

Global Impact & Significance

This approval has far-reaching consequences, from strengthening supply chains to improving patient outcomes worldwide.

Context: The Global Fight Against TB

Tuberculosis remains a major global health challenge. The availability of quality-assured medicines like Rifampicin is a critical component of the WHO's strategy to combat priority diseases.

A Threefold Victory for Public Health

✓

Combats Drug Resistance

Ensures effective first-line treatments are available, preventing the rise of deadly drug-resistant TB strains.

✓

Strengthens Supply Chains

Diversifies the pool of prequalified manufacturers, enhancing the resilience and reliability of global medicine supply.

✓

Improves Patient Outcomes

High-quality medicines directly translate to better treatment results and reduced mortality from tuberculosis.

Hebei Xingang Pharmaceutical: A Commitment to Excellence

This achievement is the result of an unwavering dedication to quality at every level of the organization.

📈

Robust Quality Systems

Implementing comprehensive systems that govern every aspect of operations, from raw material sourcing to final product release.

🔬

Advanced Facilities

Investing in state-of-the-art manufacturing facilities designed to prevent contamination and ensure optimal, consistent production.

👩‍🔬

Skilled Workforce

Employing a highly trained and competent team dedicated to upholding the most stringent GMP and international quality standards.

Hebei Xingang Pharmaceutical: WHO-PQ & GMP Approved Rifampicin for Global Health

Hebei Xingang Pharmaceutical

WHO-PQ & GMP Approved Rifampicin for Global Health Excellence

Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO-PQ and GMP Approval

A Landmark Achievement in Pharmaceutical Quality

                Breaking News: The World Health Organization has officially confirmed that Hebei Xingang Pharmaceutical Co Ltd's Rifampicin meets all WHO Prequalification standards and Good Manufacturing Practices for Active Pharmaceutical Ingredients, marking a historic milestone in global pharmaceutical excellence.
            

Introduction

In a significant development for global public health, on June 9, 2025, at 3:52 pm, the World Health Organization (WHO) officially announced that Hebei Xingang Pharmaceutical Co Ltd's Rifampicin has successfully met the stringent WHO Prequalification (WHO-PQ) standards and is fully compliant with the principles of Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs). This monumental achievement not only underscores Hebei Xingang Pharmaceutical's unwavering commitment to producing high-quality pharmaceutical products but also marks its official approval to enter the crucial WHO market.

WHO-PQ

Prequalification Achieved

GMP

Compliance Certified

2025

Year of Approval

Global

Market Access

Understanding WHO-PQ Standards

The WHO Prequalification (WHO-PQ) program is a comprehensive United Nations program established to ensure that health products procured by international agencies for developing countries meet acceptable standards of quality, safety, and efficacy. This rigorous assessment process involves a detailed evaluation of product quality, manufacturing site inspections, and laboratory testing. For a pharmaceutical product like Rifampicin to achieve WHO-PQ status, it must demonstrate consistent adherence to international norms, standards, and guidelines throughout its development and production lifecycle.

Adherence to Good Manufacturing Practices (GMP) for APIs

Good Manufacturing Practices (GMP) are a system of quality assurance that ensures products are consistently produced and controlled according to quality standards. For Active Pharmaceutical Ingredients (APIs), GMP compliance is particularly critical as APIs are the biologically active components of a drug product. The stringency of GMP in API manufacturing increases progressively from early synthesis steps to final purification and packaging, reflecting the escalating risk associated with each stage of production.

The Importance of Rifampicin in Global Health

Rifampicin, also known as rifampin, is a cornerstone antibiotic in the fight against several severe bacterial infections, most notably tuberculosis (TB) and certain forms of meningitis. As a potent ansamycin antibiotic, it plays a critical role in multi-drug regimens for TB, a disease that continues to be a major global health challenge. Its efficacy in killing or preventing the growth of various bacteria, including Mycobacterium tuberculosis and Neisseria meningitidis, makes it an indispensable medicine.

Hebei Xingang Pharmaceutical's Commitment to Quality and Innovation

Hebei Xingang Pharmaceutical Co Ltd has consistently demonstrated a profound commitment to quality, innovation, and continuous improvement within the pharmaceutical industry. This recent WHO-PQ and GMP approval for Rifampicin is not an isolated event but rather a reflection of the company's deeply ingrained philosophy of excellence. The company invests significantly in research and development, constantly seeking to enhance its manufacturing processes, optimize product formulations, and explore new therapeutic applications for its active pharmaceutical ingredients.

Future Implications and Market Entry

The official approval of Hebei Xingang Pharmaceutical Co Ltd's Rifampicin for entry into the WHO market signifies a pivotal moment for the company and for global health. This endorsement by the World Health Organization opens doors to new opportunities, allowing Hebei Xingang Pharmaceutical to significantly expand its reach and impact. The WHO-PQ status enables procurement agencies, non-governmental organizations, and national health programs worldwide to confidently source Rifampicin from Hebei Xingang, knowing it meets the highest international quality standards.

Partner with Excellence

Join us in our mission to provide world-class pharmaceutical solutions that meet the highest international standards.

Learn More About Our Products

Conclusion

The official announcement by the World Health Organization on June 9, 2025, at 3:52 pm, confirming Hebei Xingang Pharmaceutical Co Ltd's Rifampicin compliance with WHO-PQ and GMP standards, marks a significant milestone in the pharmaceutical industry. This achievement not only validates the company's unwavering dedication to producing high-quality Active Pharmaceutical Ingredients but also reinforces its crucial role in global health. By ensuring that Rifampicin, a vital antibiotic for treating tuberculosis and preventing meningitis, meets the most rigorous international benchmarks, Hebei Xingang Pharmaceutical is directly contributing to improved public health outcomes worldwide.

Hebei Xingang Pharmaceutical Co., Ltd.

Hebei Xingang Pharmaceutical Co Ltd at CPHI China 2025: Booth W7A15 - Innovating Rifamycin Solutions

CPHI China 2025: Meet Hebei Xingang Pharmaceutical at Booth W7A15

Why Visit Hebei Xingang Pharmaceutical at Booth W7A15?

1. Premium Rifamycin APIs & Intermediates

2. State-of-the-Art Manufacturing & Compliance

3. Decades of Expertise & Innovation

Global Reach, Local Expertise

Visit Booth W7A15 for:

Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO-PQ and GMP Approval

Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO Approval

Understanding the Core Pillars

WHO Prequalification

GMP for APIs

Rifampicin's Role

The Path to Prequalification

Global Impact & Significance

Context: The Global Fight Against TB

A Threefold Victory for Public Health

Combats Drug Resistance

Strengthens Supply Chains

Improves Patient Outcomes

Hebei Xingang Pharmaceutical: A Commitment to Excellence

Robust Quality Systems

Advanced Facilities

Skilled Workforce

Hebei Xingang Pharmaceutical's Rifampicin Achieves WHO-PQ and GMP Approval

A Landmark Achievement in Pharmaceutical Quality

Introduction

Understanding WHO-PQ Standards

Adherence to Good Manufacturing Practices (GMP) for APIs

The Importance of Rifampicin in Global Health

Hebei Xingang Pharmaceutical's Commitment to Quality and Innovation

Future Implications and Market Entry

Partner with Excellence

Conclusion

About Hebei Xingang Pharmaceutical

Core Product Portfolio

Rifamycin Series

Intermediate Products

Quality Certifications

Manufacturing Excellence

Advanced Facilities

R&D Strength

Global Presence

My Instagram